Newsroom
Strive to Deliver Breakthroughs
-
June 27, 2024
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
May 23, 2024
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...
View more -
March 28, 2024
Harbour BioMed Reports Full Year 2023 Financial Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...
View more -
January 24, 2024
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
Cambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...
View more -
January 19, 2024
Harbour BioMed Announces Positive Profit Alert
Cambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...
View more -
December 15, 2023
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...
View more -
August 28, 2023
Harbour BioMed Announces 2023 Interim Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...
View more -
August 28, 2023
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
Cambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023 Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...
View more -
August 08, 2023
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director
Cambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...
View more -
July 13, 2023
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1